High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study

Other authors

Universitat Ramon Llull. Facultat de Ciències de la Salut Blanquerna

Publication date

2020-09



Abstract

Background To assess whether genetically determined quantitative and qualitative HDL characteristics were independently associated with coronary artery disease (CAD). Methods We designed a two-sample multivariate Mendelian randomization study with available genome-wide association summary data. We identified genetic variants associated with HDL cholesterol and apolipoprotein A-I levels, HDL size, particle levels, and lipid content to define our genetic instrumental variables in one sample (Kettunen et al. study, n = 24,925) and analyzed their association with CAD risk in a different study (CARDIoGRAMplusC4D, n = 184,305). We validated these results by defining our genetic variables in another database (METSIM, n = 8372) and studied their relationship with CAD in the CARDIoGRAMplusC4D dataset. To estimate the effect size of the associations of interest adjusted for other lipoprotein traits and minimize potential pleiotropy, we used the Multi-trait-based Conditional & Joint analysis. Results Genetically determined HDL cholesterol and apolipoprotein A-I levels were not associated with CAD. HDL mean diameter (β = 0.27 [95%CI = 0.19; 0.35]), cholesterol levels in very large HDLs (β = 0.29 [95%CI = 0.17; 0.40]), and triglyceride content in very large HDLs (β = 0.14 [95%CI = 0.040; 0.25]) were directly associated with CAD risk, whereas the cholesterol content in medium-sized HDLs (β = −0.076 [95%CI = -0.10; −0.052]) was inversely related to this risk. These results were validated in the METSIM-CARDIoGRAMplusC4D data. Conclusions Some qualitative HDL characteristics (related to size, particle distribution, and cholesterol and triglyceride content) are related to CAD risk while HDL cholesterol levels are not.

Document Type

Article

Document version

Accepted version

Language

English

Pages

7 p.

Publisher

Elsevier

Published in

Metabolism Clinical and Experimental, 2020, 112: 154351

Grant Agreement Number

info:eu-repo/grantAgreement/MINECO/ISCIII i FEDER/CD17/00122

info:eu-repo/grantAgreement/MINECO/ISCIII i FEDER/IFI14/00007

info:eu-repo/grantAgreement/MINECO/ISCIII i FEDER/PI18/00017

info:eu-repo/grantAgreement/MRC/MR/K501256/1

info:eu-repo/grantAgreement/MRC/MR/N013468/1

info:eu-repo/grantAgreement/MINECO/PN I+D/BES-2014-069718

info:eu-repo/grantAgreement/MINECO/PN I+D/SAF2015-71653-R

info:eu-repo/grantAgreement/EU/H2020/796216

info:eu-repo/grantAgreement/SUR del DEC/SGR/2017 SGR 222

Recommended citation

This citation was generated automatically.

Rights

© Elsevier. Tots els drets reservats

This item appears in the following Collection(s)